Teva Pharmaceutical Industries ADR (TEVA)

$35.81 -0.03 (-0.08%)
Market Cap 41.21B
Revenue (ttm) 17.26B
Net Income (ttm) 1.41B
EPS (ttm) N/A
PE Ratio 12.67
Forward PE 14.34
Profit Margin 8.18%
Debt to Equity Ratio 2.02
Volume 4,625,400
Avg Vol 7,034,528
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 52%
Beta 0.86
Analysts Strong Sell
Price Target $39.45

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
layahoo
layahoo May. 12 at 9:56 PM
$TEVA What happened to the 33 prediction fools?
1 · Reply
layahoo
layahoo May. 12 at 7:20 PM
$TEVA Go Teva!
0 · Reply
BirdWithBigBalls
BirdWithBigBalls May. 12 at 1:52 PM
$TEVA seems like this was a low average price. Lucky to liquidate with profit. Ill be back to short at $40.
1 · Reply
shoagh12
shoagh12 May. 11 at 1:33 PM
$TEVA 40$ soon
0 · Reply
Noname2022
Noname2022 May. 9 at 5:34 PM
$AKBA $TEVA Teva generic only became available 3/12/26 Will be interesting to watch Q2 impact on revenue
0 · Reply
TheDudeRooster
TheDudeRooster May. 8 at 5:12 PM
$TEVA A little early for the daily scalp on the afternoon run-up, but what the heck.
0 · Reply
Guinness511
Guinness511 May. 8 at 4:39 PM
$TEVA gap down to 33 needs to close first
2 · Reply
Contrarian_Dan
Contrarian_Dan May. 7 at 2:12 PM
$TEVA Its coming.
0 · Reply
Estimize
Estimize May. 7 at 2:08 PM
Wall St is expecting 0.60 EPS for $TEVA Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/teva?chart=historical&metric_name=eps&utm_co
0 · Reply
StockSqueeze_
StockSqueeze_ May. 6 at 8:08 PM
Live Account Update Up 0.27%. $PR sold for a loss this morning. I picked up more $ET since it was down today. Also picked up $APLD from the Diamond channel and $HST from the Free one. $TEVA finished the day strong to help keep us green for the day. I did not beat the market, did you? Back at it tomorrow.
0 · Reply
Latest News on TEVA
Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-05-07T23:01:52.000Z - 5 days ago

Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Teva price target raised to $40 from $38 at Barclays

2026-05-07T10:11:42.000Z - 6 days ago

Teva price target raised to $40 from $38 at Barclays

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

2026-05-06T13:56:40.000Z - 6 days ago

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-05-05T21:06:13.000Z - 7 days ago

Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Teva to Present at the BofA Securities Health Care Conference

Mon, 04 May 2026 16:30:00 -0400 - 8 days ago

Teva to Present at the BofA Securities Health Care Conference

TEVA Maintained by JP Morgan -- Price Target Raised to $40.00

2026-05-01T00:01:08.000Z - 12 days ago

TEVA Maintained by JP Morgan -- Price Target Raised to $40.00

TEVA Maintained by UBS -- Price Target Raised to $42.00

2026-04-30T22:01:04.000Z - 12 days ago

TEVA Maintained by UBS -- Price Target Raised to $42.00

TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00

2026-04-30T18:36:45.000Z - 12 days ago

TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00

TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45

2026-04-30T16:33:14.000Z - 12 days ago

TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45

Teva price target raised to $50 from $45 at Goldman Sachs

2026-04-30T16:21:59.000Z - 12 days ago

Teva price target raised to $50 from $45 at Goldman Sachs

Teva price target raised to $40 from $35 at JPMorgan

2026-04-30T15:36:02.000Z - 12 days ago

Teva price target raised to $40 from $35 at JPMorgan

Teva price target raised to $42 from $41 at Piper Sandler

2026-04-30T12:49:01.000Z - 13 days ago

Teva price target raised to $42 from $41 at Piper Sandler

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Thu, 30 Apr 2026 08:30:00 -0400 - 13 days ago

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva price target raised to $42 from $36 at UBS

2026-04-30T10:56:16.000Z - 13 days ago

Teva price target raised to $42 from $36 at UBS

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

2026-04-30T08:44:00.000Z - 13 days ago

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...

2026-04-30T07:05:48.000Z - 13 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...

Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

2026-04-30T05:06:28.000Z - 13 days ago

Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors

2026-04-29T22:21:37.000Z - 13 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors

Teva price target raised to $45 from $42 at Truist

2026-04-29T19:30:23.000Z - 13 days ago

Teva price target raised to $45 from $42 at Truist

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Wed, 29 Apr 2026 14:22:48 -0400 - 13 days ago

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Wed, 29 Apr 2026 13:52:33 -0400 - 13 days ago

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Unusually active option classes on open April 29th

2026-04-29T16:37:10.000Z - 13 days ago

Unusually active option classes on open April 29th

BBAI CVNA CVS FCEL JOBY NTLA PLUG

TEVA Forecasts Steady Revenue Growth and Strong Margins

2026-04-29T16:31:07.000Z - 13 days ago

TEVA Forecasts Steady Revenue Growth and Strong Margins

TEVA Expects Positive Impact from Emalex Acquisition

2026-04-29T16:29:34.000Z - 13 days ago

TEVA Expects Positive Impact from Emalex Acquisition

TEVA Forecasts $700 Million in Savings by 2027

2026-04-29T15:54:59.000Z - 13 days ago

TEVA Forecasts $700 Million in Savings by 2027

TEVA Positioned for Margin Growth and Strategic Moves

2026-04-29T15:51:43.000Z - 13 days ago

TEVA Positioned for Margin Growth and Strategic Moves

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

2026-04-29T15:47:03.000Z - 13 days ago

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

TEVA Anticipates Gradual Margin Growth in 2023

2026-04-29T15:31:40.000Z - 13 days ago

TEVA Anticipates Gradual Margin Growth in 2023

Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

2026-04-29T15:00:05.000Z - 13 days ago

Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

DBEF, SPOT, TEVA, NBIS: ETF Outflow Alert

2026-04-29T14:54:09.000Z - 13 days ago

DBEF, SPOT, TEVA, NBIS: ETF Outflow Alert

Teva Pharmaceutical (TEVA) Reports Q1 Earnings Beat, Adjusts 2026 Outlook

2026-04-29T13:59:54.000Z - 13 days ago

Teva Pharmaceutical (TEVA) Reports Q1 Earnings Beat, Adjusts 2026 Outlook

Teva Pharmaceutical (TEVA) Reports Strong Q1 Earnings, Beats Expectations

2026-04-29T13:13:05.000Z - 13 days ago

Teva Pharmaceutical (TEVA) Reports Strong Q1 Earnings, Beats Expectations

Teva Pharmaceutical (TEVA) Exceeds Q1 Expectations but Lowers Full-Year Earnings Outlook

2026-04-29T13:06:06.000Z - 13 days ago

Teva Pharmaceutical (TEVA) Exceeds Q1 Expectations but Lowers Full-Year Earnings Outlook

Teva Surges As Its New Growth Strategy Hits A Key Inflection Point

2026-04-29T12:58:30.000Z - 13 days ago

Teva Surges As Its New Growth Strategy Hits A Key Inflection Point

TEVA Adjusts FY26 Revenue and EBITDA Projections

2026-04-29T12:54:04.000Z - 14 days ago

TEVA Adjusts FY26 Revenue and EBITDA Projections

Teva Pharmaceutical (TEVA) Q1 2026: Non-GAAP EPS $0.53 vs. $0.12 est., Revenue $3.98B vs. $3. ...

2026-04-29T12:33:14.000Z - 14 days ago

Teva Pharmaceutical (TEVA) Q1 2026: Non-GAAP EPS $0.53 vs. $0.12 est., Revenue $3.98B vs. $3. ...

Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets

2026-04-29T12:08:32.000Z - 14 days ago

Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets

Teva Pharmaceutical Industries Transcript: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 14 days ago

Teva Pharmaceutical Industries Transcript: M&A announcement

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 14 days ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Teva (TEVA) Announces Acquisition of Emalex Biosciences

2026-04-29T11:50:53.000Z - 14 days ago

Teva (TEVA) Announces Acquisition of Emalex Biosciences

Teva reports Q1 EPS 53c, consensus 46c

2026-04-29T11:40:14.000Z - 14 days ago

Teva reports Q1 EPS 53c, consensus 46c

Teva Acquires Emalex Biosciences, Expands Neuroscience Pipeline

2026-04-29T11:28:41.000Z - 14 days ago

Teva Acquires Emalex Biosciences, Expands Neuroscience Pipeline

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Wed, 29 Apr 2026 07:05:54 -0400 - 14 days ago

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Wed, 29 Apr 2026 07:00:00 -0400 - 14 days ago

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva to acquire Emalex Biosciences for $700M at closing

2026-04-29T10:37:59.000Z - 14 days ago

Teva to acquire Emalex Biosciences for $700M at closing

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Wed, 29 Apr 2026 06:30:00 -0400 - 14 days ago

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Notable companies reporting before tomorrow’s open

2026-04-28T18:25:46.000Z - 14 days ago

Notable companies reporting before tomorrow’s open

ABBV BIIB CAR EAT ETSY GD GEHC

Teva put volume heavy and directionally bearish

2026-04-28T18:15:20.000Z - 14 days ago

Teva put volume heavy and directionally bearish

Teva Pharmaceutical (TEVA) Prepares for Q1 Earnings Announcement

2026-04-28T18:01:59.000Z - 14 days ago

Teva Pharmaceutical (TEVA) Prepares for Q1 Earnings Announcement

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.

Mon, 27 Apr 2026 21:43:00 -0400 - 15 days ago

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.

Teva put volume heavy and directionally bearish

2026-04-20T16:35:10.000Z - 22 days ago

Teva put volume heavy and directionally bearish

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva price target raised to $42 from $38 at BofA

2026-04-09T13:35:58.000Z - 4 weeks ago

Teva price target raised to $42 from $38 at BofA

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Releases Q1 2026 Aide Memoire

Mar 19, 2026, 4:30 PM EDT - 7 weeks ago

Teva Releases Q1 2026 Aide Memoire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Mar 19, 2026, 4:30 PM EDT - 7 weeks ago

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva to Present at the Upcoming Investor Conferences in March

Feb 24, 2026, 4:30 PM EST - 2 months ago

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Feb 20, 2026, 2:43 PM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 3 months ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:31 AM EST - 3 months ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 28, 2026, 7:00 AM EST - 3 months ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 27, 2026, 8:00 AM EST - 3 months ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 5:02 PM EST - 4 months ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Why Investors Are So Optimistic on Teva

Jan 12, 2026, 10:46 AM EST - 4 months ago

Why Investors Are So Optimistic on Teva

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 6:00 PM EST - 4 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:00 PM EST - 4 months ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:30 PM EST - 4 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 24, 2025, 8:36 AM EST - 4 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 19, 2025, 3:40 AM EST - 5 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 9, 2025, 8:00 AM EST - 5 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 25, 2025, 8:10 AM EST - 6 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 21, 2025, 4:30 PM EST - 6 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Teva seeks startups to help solve global pharmaceutical challenges

Nov 19, 2025, 8:07 AM EST - 6 months ago

Teva seeks startups to help solve global pharmaceutical challenges

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 7, 2025, 6:00 PM EST - 6 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:02 PM EST - 6 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 9:14 AM EST - 6 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:44 AM EST - 6 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Nov 5, 2025, 7:00 AM EST - 6 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 31, 2025, 4:30 PM EDT - 6 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 30, 2025, 11:45 AM EDT - 6 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 20, 2025, 4:30 PM EDT - 7 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 10, 2025, 3:00 PM EDT - 7 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 8 months ago

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 4:30 PM EDT - 8 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 20, 2025, 10:15 PM EDT - 8 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 16, 2025, 4:30 PM EDT - 8 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Colorado must face Teva's lawsuit over free allergy pen law

Sep 5, 2025, 3:57 PM EDT - 8 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Sep 2, 2025, 4:30 PM EDT - 9 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 9:17 AM EDT - 9 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 19, 2025, 9:00 AM EDT - 9 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

US FDA approves Teva's Ajovy for migraine prevention in children

Aug 5, 2025, 6:16 PM EDT - 10 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Teva CEO: Our supply chain puts us in a strong position

Jul 30, 2025, 12:40 PM EDT - 10 months ago

Teva CEO: Our supply chain puts us in a strong position

Teva Pharm Q2 profit beats estimates as branded drugs gain

Jul 30, 2025, 7:21 AM EDT - 10 months ago

Teva Pharm Q2 profit beats estimates as branded drugs gain

Teva Releases Q2 2025 Aide Memoire

Jun 26, 2025, 4:30 PM EDT - 11 months ago

Teva Releases Q2 2025 Aide Memoire

layahoo
layahoo May. 12 at 9:56 PM
$TEVA What happened to the 33 prediction fools?
1 · Reply
layahoo
layahoo May. 12 at 7:20 PM
$TEVA Go Teva!
0 · Reply
BirdWithBigBalls
BirdWithBigBalls May. 12 at 1:52 PM
$TEVA seems like this was a low average price. Lucky to liquidate with profit. Ill be back to short at $40.
1 · Reply
shoagh12
shoagh12 May. 11 at 1:33 PM
$TEVA 40$ soon
0 · Reply
Noname2022
Noname2022 May. 9 at 5:34 PM
$AKBA $TEVA Teva generic only became available 3/12/26 Will be interesting to watch Q2 impact on revenue
0 · Reply
TheDudeRooster
TheDudeRooster May. 8 at 5:12 PM
$TEVA A little early for the daily scalp on the afternoon run-up, but what the heck.
0 · Reply
Guinness511
Guinness511 May. 8 at 4:39 PM
$TEVA gap down to 33 needs to close first
2 · Reply
Contrarian_Dan
Contrarian_Dan May. 7 at 2:12 PM
$TEVA Its coming.
0 · Reply
Estimize
Estimize May. 7 at 2:08 PM
Wall St is expecting 0.60 EPS for $TEVA Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/teva?chart=historical&metric_name=eps&utm_co
0 · Reply
StockSqueeze_
StockSqueeze_ May. 6 at 8:08 PM
Live Account Update Up 0.27%. $PR sold for a loss this morning. I picked up more $ET since it was down today. Also picked up $APLD from the Diamond channel and $HST from the Free one. $TEVA finished the day strong to help keep us green for the day. I did not beat the market, did you? Back at it tomorrow.
0 · Reply
Love_To_Learn
Love_To_Learn May. 6 at 12:01 PM
$TEVA MANIPULATING THE 35.12 FILLER UNDER US IN PREPARATION
0 · Reply
Love_To_Learn
Love_To_Learn May. 6 at 11:33 AM
$TEVA $APLD EXECUTING !
0 · Reply
CoachHendo
CoachHendo May. 6 at 8:48 AM
$TEVA super bullish! LT!
0 · Reply
StockSqueeze_
StockSqueeze_ May. 5 at 11:18 PM
Live Account Update Up 1.86%. Not gonna lie, I needed a green day. Sold $ACHC this morning when it hit the stop loss target. Still holding $PR which can't make up it's mind. Picked up $NVTS and sold when it hit the target price. Also grabbed $TEVA and $ET Let's have another positive day tomorrow! I beat the market today. How did you do?
0 · Reply
BirdWithBigBalls
BirdWithBigBalls May. 5 at 4:28 PM
$TEVA is this a good average to short?
4 · Reply
Hopewisper
Hopewisper May. 5 at 1:35 PM
$TEVA where do you think we are end 2027? 80$ 100 $ 120 $..... maby 150$....
0 · Reply
Hopewisper
Hopewisper May. 5 at 5:35 AM
$TEVA Just waiting ....
0 · Reply
layahoo
layahoo May. 4 at 9:04 PM
$TEVA Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026
0 · Reply
StockSqueeze_
StockSqueeze_ May. 4 at 8:16 PM
Live Account Update Down 2.02% today. Not great. Sold $MCHP for a nice gain this morning. Still holding $PR which is green. The red has all come from $ACHC and $TEVA which I grabbed today and will most likely bounce back tomorrow. I did not beat the market today. Back at it again tomorrow.
0 · Reply
Hopewisper
Hopewisper May. 4 at 5:50 PM
$TEVA What's not to like$$$$$$$$$$$🌞
0 · Reply
CapitalMonk
CapitalMonk May. 4 at 3:01 PM
$TEVA Price: $35.74 (+2.26%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.82% RSI: 71.2 | Momentum: Strong Momentum Volume: -63.4% vs avg Volatility: 3.13% Support: $28.94 | Resistance: $36.02 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Quantumup
Quantumup May. 4 at 12:11 PM
H.C. Wainwright⬆️ $CORT's PT to $75.00, kept at a Buy, and said: On April 30, Corcept reported 1Q26 financial results and hosted its earnings call. $NVS $TEVA XERS RHHBY MRK ABBV JAZZ BMY Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2051272839689310703?s=20
0 · Reply